Clinical Research
搜索文档
Thermo Fisher to acquire clinical trial data firm Clario for $8.9B
Yahoo Finance· 2025-10-29 19:41
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Thermo Fisher Scientific will acquire clinical trial data firm Clario Holdings for $8.9 billion in cash, the companies announced Wednesday. Clario is currently held by a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven. In addition, Thermo has agreed to pay $125 million in January 2027, and up to $400 million in payments base ...
Best Momentum Stock to Buy for Oct. 28th
ZACKS· 2025-10-28 20:16
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Oct. 28th:Medpace (MEDP) : This company, which is a scientifically-driven, global, full-service clinical contract research organization which provides Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries, has a Zacks Rank #1 (Strong Buy), and witnessed the Zacks Consensus Estimate for its current yearearnings increasing 3.6% over the last 60 days.Med ...
Why Medpace Popped 13% This Week
Yahoo Finance· 2025-10-25 01:05
Key Points Medpace's revenue growth was strong last quarter. The company is building up a backlog as the clinical trial sector recovers. Shares of Medpace are up 100% since the beginning of this year. 10 stocks we like better than Medpace › Shares of Medpace (NASDAQ: MEDP) zoomed 13% higher this week as of 11:49 a.m. ET on Friday, according to data from S&P Global Market Intelligence. The clinical research organization that helps pharmaceutical companies perform outsourced research and trial test ...
Navigating a Mixed Market: Tech Earnings and AI Developments Drive Wednesday’s Trading
Stock Market News· 2025-10-22 18:07
市场整体态势 - 美股市场呈现复杂交易格局 主要股指期货表现不一 纳斯达克100指数和道琼斯工业平均指数期货小幅走低 而标普500指数期货微幅上涨 [1][2] - 市场主要受企业新闻 关键财报发布和人工智能领域进展的影响 [1][8] - 当日印度股市因排灯节休市 可能对国际资金流动产生潜在影响 [3] 主要公司动态与财报 - 特斯拉预计公布2025年第三季度财报 分析师预测每股收益0.48美元 营收约249.8亿美元 部分分析师更为乐观 预测非GAAP每股收益0.66美元 营收达284亿美元 同时特斯拉宣布召回约12,963辆2025款Model 3和2026款Model Y 以解决电池包接触器潜在故障 [4][7] - 微软首席执行官2025财年总薪酬升至创纪录的9650万美元 增幅达22% 公司近期将季度股息提高至每股0.91美元 [11] - 苹果据报因消费者需求低于预期 "大幅"削减新款iPhone Air的生产订单 将重点转向其他iPhone 17机型 导致其美股盘前交易中股价下跌0.7% [11] - 谷歌母公司Alphabet股价周二下跌约2% 因OpenAI推出新AI浏览器ChatGPT Atlas 但盘后交易中因可能与AI初创公司Anthropic达成数十亿美元云计算协议而反弹3.1% [11] 行业趋势与重大事件 - 人工智能持续推动科技板块增长 英伟达 超微半导体和博通等公司被看好将受益于AI相关交易激增带来的营收增长 英伟达与台积电在美国实现首批Blackwell芯片晶圆生产 其股价在2025年已上涨31% [11] - 除特斯拉外 当日发布财报的公司还包括IBM SAP 波士顿科学 Medpace控股 莫利纳医疗保健和赛默飞世尔科技 微软和苹果将分别于10月29日和30日发布财报 [5] - 凯悦酒店集团与首旅如家酒店集团达成战略总特许经营协议 计划在中国推出50家凯悦尚选酒店 拓展长住细分市场 佳能公司宣布其EOS系列RF/EF可换镜镜头产量突破1.7亿枚 创下新世界纪录 [11] 经济数据与政策 - 美国劳工统计局计划于美东时间上午10点发布2025年8月的州级职位空缺和劳动力流动调查数据 此外还将发布能源信息署报告 [6] - 欧洲央行行长克里斯蒂娜·拉加德和副行长路易斯·德金多斯将发表讲话 可能为全球货币政策方向提供线索 [6]
ClearBridge Select Strategy Q3 2025 Commentary
Seeking Alpha· 2025-10-18 00:54
市场概述 - 美国股市在第三季度保持上涨势头,标普500指数上涨8.1%,罗素3000指数上涨8.2% [2] - 投资者乐观情绪源于好于预期的关税结果、7月通过的《One Big Beautiful Bill Act》、预期的美联储降息以及稳健的企业盈利 [2] - 成长股领涨大盘,罗素3000成长指数上涨10.4%,表现优于价值指数近500个基点 [3] - 罗素2500成长指数(包含许多中小型公司)当季上涨10.7%,表现超越大盘 [3] 投资策略表现 - 策略连续第二个季度跑赢基准指数,贡献均衡地来自防御性必需消费品板块、成长型通信服务和IT板块的颠覆者以及周期性工业板块的独特优势 [4] - 策略的绝对收益贡献来自11个行业板块中的8个,主要贡献来自IT板块,主要拖累来自金融板块 [25] - 相对于基准指数,整体个股选择贡献了业绩,特别是在必需消费品和通信服务板块的选股、超配IT板块和低配金融板块推动了业绩 [26] - 个股层面,主要的相对贡献者包括AppLovin、Reddit、Comfort Systems、Shopify和L3Harris Technologies,主要的拖累因素包括对MercadoLibre、ServiceNow、Fortinet的持仓以及未持有Alphabet和特斯拉 [27] 行业与公司表现:积极贡献 - 必需消费品板块中,Performance Food Group因激进投资者倡导其被竞争对手U.S. Foods收购的消息而受到提振,Grocery Outlet和Casey's General Stores也是该板块的稳健贡献者 [5] - 通信服务板块中,社交媒体平台Reddit广告收入同比增长84%,活跃广告商数量增加50%,国际扩张取得显著进展,日活跃用户增长32% [6] - IT板块中,移动应用用户获取和变现平台提供商AppLovin股价因强劲的二季度财报和对其新兴电子商务业务的乐观情绪而翻倍,其AI驱动的需求生成能力被视为一流 [7] - 工业板块持仓带来多元化贡献,国防承包商L3Harris Technologies受益于对空防和导弹防御支出需求的增长,Comfort Systems作为AI数据中心冷却系统提供商需求稳定 [8] 行业与公司表现:面临挑战 - 非必需消费品和金融板块面临业绩阻力,拉丁美洲电商提供商MercadoLibre因在关键市场应对竞争而延长免费送货并降低商户费用,这可能影响短期盈利能力,且公司受到获利了结的冲击,未持有特斯拉也拖累业绩 [9] - 支付处理软件提供商Shift4 Payments因二季度业绩略逊预期而股价受挫,但其提高了全年营收、支付量和营业利润的指引 [10] - 应用软件制造商ServiceNow、Fortinet、HubSpot和DocuSign因市场担忧生成式AI可能颠覆其商业模式而股价下跌,但此类风险被认为被夸大且需要多年才能构成威胁 [11] 投资组合调整:新开仓位 - 当季新建立8个仓位,增加了生物科技领域的敞口,买入Regeneron Pharmaceuticals和Vertex Pharmaceuticals [12] - Regeneron在眼科、皮肤科、肿瘤学和心脏病学领域拥有领先疗法,其新版Eylea销售额激增,皮炎治疗药物Dupixent全球销售额强劲 [12] - Vertex是囊性纤维化领域的领先生物科技公司,其下一个重大机会在疼痛治疗领域,慢性疼痛临床试验的时间安排上的失望使得可以以相对其产品管线而言适中的估值建立仓位 [13] - 买入美国最大的竞争性电力生产商Vistra,其拥有41吉瓦的发电机组,地域和燃料来源多元化,公司有望从其主要电力市场的紧缩条件中受益,并可能获得联邦对核电站的补贴 [14] - 参与了商业航天行业发射服务提供商Firefly Aerospace的IPO,公司拥有11亿美元订单储备,并与主要航空航天国防承包商诺斯罗普·格鲁曼和洛克希德·马丁合作 [15] - 参与了设计软件公司Figma的IPO,但在其首日股价大幅上涨后退出该仓位 [15] 投资组合调整:退出仓位 - 退出临床研究组织ICON,因生物科技融资挑战、政府资金不确定性及其他监管变化在2025年加剧,降低了对CRO业务复苏时机的信心 [16] - 减持薪资和人力资源软件提供商Paylocity,因其在低利率和就业趋势疲软的环境中表现挣扎,更看好健康储蓄账户提供商Health Equity [17] - 卖出云软件开发商Adobe,动机是担忧其产品套件的高渗透率以及竞争风险,AI降低了准入壁垒并使其部分业务商品化 [18] 市场展望 - 市场从4月初低点延续反弹,验证了解决全球关税问题的关键在于总统的立场,而这一立场可能迅速逆转,如10月初因中美贸易战再度升温而出现的抛售所示 [19] - 股市表现的拓宽并不需要利率大幅下降,只需利率逐步回归正常水平且波动性降低,同时商业活动需要更多关于关税的明确性,美联储已在利率方面开始行动,关税明确性稳步改善 [19] - 市场领导力拓宽的长期预期在第三季度出现进展迹象,小盘股罗素2000指数表现显著领先于大盘股指数,中小型股的每股收益增长持续改善,预计明年将赶上"七巨头" [20][23] - 宏观背景预计仍将颠簸,但投资组合已布局为在各种市场和经济情景下都能表现良好,采取平衡策略,持有拥有有机增长动力和强大管理团队的公司,具备灵活性以长期持有公司并伴随其业务周期 [24] 其他投资组合变动 - 在工业板块增加了Kratos Defense & Security Solutions和Casella Waste Systems的仓位,在IT板块增加了Netskope和Monday.com的仓位 [28] - 卖出了必需消费品板块的Constellation Brands和IT板块的Gitlab [28]
5 Value Picks to Ride Out US-China Trade Rift & Government Shutdown
ZACKS· 2025-10-13 20:35
Key Takeaways The U.S. market faces trade and policy turbulence amid renewed tariff threats and a shutdown.Value investing gains traction, with high earnings yield signaling undervalued opportunities. AAUC, MU, FTRE, STNE, and DINO emerge as top picks meeting strong earnings and value criteria.The U.S. market faces a turbulent week as multiple pressures collide — renewed U.S.-China trade tensions, an ongoing government shutdown and the kickoff of the third-quarter earnings season. U.S. President Trump’s war ...
Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
Globenewswire· 2025-10-08 20:18
MORRISVILLE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its third FDA inspection, further affirming the quality and compliance of its Direct-to-Patient Site for clinical research. The inspection concluded with a No Action Indicated (NAI) categorization recommendation by the inspector, with no objectionable conditions noted and no Form 483 issued. The review centered on Science 37’s contribution in ...
Four Pharma Firms Ditched Medicine Development And Dived Into Crypto
Yahoo Finance· 2025-10-01 02:11
Photo by BeInCrypto Helius Medical Technologies is the latest medical company to pivot to a digital asset treasury, making it the fourth firm to take a similar step in recent months. These firms increasingly consider crypto investments a viable alternative to generate the growth their main drug development efforts have struggled to provide. Helius Trades Neurotech for Solana Helius Medical Technologies officially rebranded as Solana Company this week, becoming the latest medical corporation to pivot its ...
FOXO TECHNOLOGIES INC. ANNOUNCES CLOSING OF VECTOR BIOSOURCE INC.
Globenewswire· 2025-09-22 20:17
收购交易核心信息 - FOXO Technologies Inc 宣布完成对生物科技行业信息、数据和生物样本供应商Vector Biosource Inc的收购 [1] - 收购对价包括50万美元现金、6万股E系列累积可赎回优先股(票面价值150万美元)以及购买200万美元普通股的认股权证 [2] - 额外或有对价为最多8万股E系列优先股(票面价值最高200万美元),取决于未来12至24个月内达成特定收入和现金回收里程碑 [2] - FOXO同意为Vector的增长计划提供最高120万美元资金 [2] 被收购方财务与业务概况 - Vector Biosource Inc服务于生物技术、临床研究和制药研究行业 [1] - Vector在2025年第二季度实现净收入约22.5万美元(年化运行率约为90万美元) [1] - 收购后Vector预计将实现显著增长 [1] 公司管理层评论 - FOXO首席执行官Seamus Lagan表示期待与Vector高级管理层合作开发内外增长机会 [2] - Vector首席执行官Frank Dias, Jr. 认为与FOXO的合作将使Vector实现其积极的增长计划 [2] 收购方业务结构 - FOXO Technologies Inc拥有并运营三家主要子公司 [4] - Rennova Community Health, Inc. 拥有并运营位于田纳西州东部的关键准入指定医院Big South Fork医疗中心 [4] - Myrtle Recovery Centers, Inc. 是田纳西州东部一家拥有30张床位的行为健康设施,提供戒毒、住院治疗及门诊服务 [4] - FOXO Labs, Inc. 是一家致力于通过开发尖端技术和产品解决方案来改善人类健康和寿命的生物技术公司 [5]
Datavant and Indegene partner to improve trial subject recruitment
Yahoo Finance· 2025-09-22 17:53
Data collaboration platform Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical studies. This partnership places particular emphasis on studies concerning rare diseases and other complex conditions. By leveraging Datavant's data enrichment offerings and Indegene's NEXT Patient Recruitment platform, the collaboration allows biopharma companies to reduce screen failures at the site level. The partnership also enables quicker enrolment ...